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In studies on the effects of therapy (or other interventions),
the randomized controlled trial (RCT) is an almost unbeatable
standard in clinical research. The value of RCTs leaves
unabated the valuable contributions of observational studies
to medicine. This paper discusses some limitations of RCTs
providing examples where these are not possible,
inappropriate, inadequate, or unnecessary. Thereafter, it
focuses on observational studies and gives a number of
examples of studies on etiology, diagnosis, prognosis, and
adverse effects, where observational designs have provided
answers to research questions that could not have been
answered by RCTs. Strengths and weaknesses of the different
observational study designs are discussed. Finally, it is
concluded that both observational studies and RCTs fulfill a
complementary and valuable role in nephrology.
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The value of observational studies in comparison to
randomized controlled clinical trials (RCTs) has been subject
of extensive debate. The previous paper in this series has
illustrated that in studies on the effects of therapy (or other
interventions), the RCT is an almost unbeatable standard in
clinical research.1 The reason for this is that in an RCT, the
randomization procedure helps to prevent selection bias by
the clinician by breaking the link between the clinician’s
therapy prescription and the patient’s prognosis.2 This has
resulted in the so-called ‘hierarchy of study designs’ (Figure 1)
that, in addition to other aspects of the quality of studies,
may be used for grading the level of evidence in studies on
the effects of therapy.
Although randomization of large groups of patients will
often result in a similar distribution of known and unknown
variables in the experimental and the control group, it is
unlikely that the intended balance will be achieved for all
patient characteristics. That is easy to understand if we just
think of the many prognostic factors that are determined by
the human genome. Even in very large trials we can be certain
that also after randomization, quite a number of genetic
differences between the experimental and the control group
will remain. Though the balance will not be complete, the
randomization process does guarantee that any differences
between the two groups are due to chance2 and not to the
doctor’s choice.
The value of RCTs leaves unabated the valuable contribu-
tions of observational studies (in particular etiologic studies)
to medicine. After discussing some limitations of RCTs, this
article will focus on the strengths of observational studies and
give a number of examples where observational studies have
provided answers to research questions that could not have
been answered by an RCT. For the explanation of the
different study designs, we also refer to the previous paper in
this series.1
RCTS ARE NOT A PANACEA
Black3 stated that in a number of cases, RCTs are impossible,
inappropriate, inadequate, or unnecessary. In the following
paragraphs, we will give examples for each of those
categories.
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RCTs are not possible
Given the extremely large number of existing and new health
care interventions, it will not be possible to test all of them in
an RCT. This is not only due to the scale of the task but also
to financial constraints, as depending on the type and size of
the trial, RCTs may cost millions or tens of millions of euros
which makes them much more expensive than observational
studies. Another reason is that ethical objections may prevent
interventions to be tested within an RCT setting, especially
when well-accepted best practice is compared with treatment
with an unknown or probably less favorable outcome. It is,
for example, hard to imagine that a Medical Ethical
Committee will grant permission for an RCT investigating
whether there is a difference in patient survival between
dialysis and conservative treatment in end-stage renal disease.
The same will be true for an RCT aiming to quantify the
difference in outcome between dialysis and renal transplanta-
tion. Although most of us will agree that observational studies
in this latter area may suffer from ‘selection by prognosis,’ as
transplanted patients already have a better prognosis before
transplantation, we cannot but rely on the results of
observational studies such as the one by Wolfe et al.4
RCTs may be inappropriate
Examples of cases where RCTs may be possible, but
inappropriate include the detection (or the accurate mea-
surement of the frequency) of adverse events that are rare or
that take a number of years to develop. Most trials are simply
too small and have insufficient follow-up2,3 to detect, for
example, adverse effects of drugs that are fewer than about
one per 200/year or that take more than 1 year to develop.2
To investigate this type of events case–control studies or large
scale cohort studies are needed.
RCTs may be inadequate
The results of RCTs may have low generalizability. This is due
to the fact that RCTs tend to be conducted in selected patient
populations due to their restrictive in- and exclusion criteria.
For example, the RCT comparing survival on hemodialysis
versus peritoneal dialysis that was performed within the
NEtherlands COoperative Study on the Adequacy of Dialysis
(NECOSAD) cohort included only 38 (3%) of the 1232
patients in the total cohort study population, as 459 (37%)
patients did not fulfill the inclusion criteria and 735 (60%)
had a preference for either modality.5 Strong selection was
therefore one of the problems of the study. Other selection
effects may arise from the fact that health professionals taking
part in RCTs are frequently unrepresentative for those that
provide everyday health care, as they have an interest in the
subject or belong to the ‘innovators.’ Finally, whereas a
decade ago most RCTs primarily took place in atypical
settings like teaching hospitals,3,6 nowadays contract research
organizations seem to be shifting their focus to private
practices. Considering the generalizability of study results,
this means that the results of RCTs carried out in narrowly
defined groups and circumstances may only be valid for those
specific groups in these particular situations instead of for all
patients. In this regard, observational studies have the
advantage of reflecting the actual prescribing in health care
and the advantages of typically including broader patient
populations7 and also non-teaching centers6 resulting in a
higher generalizability of study results.
RCTs may be unnecessary
There are a number of historical examples where the effects
of health interventions were dramatic (e.g., insulin in type 1
diabetes mellitus and neostigmine in myasthenia gravis). In
those exceptional cases, observational studies were suffi-
ciently adequate to demonstrate the effectiveness of those
interventions.3,8
In summary, although RCTs are the gold standard in
studies on the effects of therapy, this study design has also
limitations depending on the research question and on the
way the studies are conducted.
OBSERVATIONAL STUDIES: WHERE DO THEY APPLY?
Observational studies on the effects of therapy are usually the
first step to generate and test hypotheses, but they have less
potential in making causal inferences than RCTs. Quite a
number of observational studies, however, do not focus on
effects of therapy, but seek to answer research questions
relating to etiology, diagnosis, prognosis, or adverse effects,
areas where RCTs are inappropriate or even impossible. In
the following paragraphs, we will present a number of
examples of the use of observational designs for this type of
studies in nephrology, and we will discuss the strengths and
weaknesses of each study design (see also Table 1).
Case report and case series
Case reports and case series are descriptive study designs
providing detailed descriptions of cases without the use of a
control group. In a series of 13 patients with chronic renal
failure Casadevall et al.9 described a relationship between the
RCTs
Potential to establish
causality in studies on
the effects of therapy
Cohort studies
Case–control studies
Case reports and case series
Figure 1 | Contribution of different study designs to clinical
research. The increase in evidence from the bottom to the top only
applies to studies on the effect of therapy (or other interventions).
Footnote: As cross-sectional studies play a very limited role in studies
on effects of therapy, this study design was not included in the figure.
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use of recombinant human erythropoietin (epoetin) and the
development of pure red-cell aplasia. Their paper is an
excellent example of the discovery of a new and rare adverse
event as a result of the exposure to a specific drug. After
publication of this paper, evidence about more cases became
available from observational studies and eventually the likely
cause of the problem was found. In the meantime, this case
series had a large impact on the market for epoetin.
Another case series on the reversal of diabetic nephropathy
as a late effect of pancreas transplantation in patients with
type 1 diabetes mellitus was published by Fioretto et al.10
Their paper shows how this study design can be used to
provide insight into the mechanisms of disease and recovery.
Other potential roles of case reports and case series include
the recognition and description of new diseases, medical
education, and audit and the recognition of rare manifesta-
tions of disease.11 These study designs are helpful in
generating hypotheses that may later be studied further or
tested in analytic study designs.
Cross-sectional study
Within cross-sectional studies, the exposure and the outcome
are usually assessed at the same time. This hampers the
interpretation of associations, as the data will usually not tell
the investigator which came first: the ‘exposure’ or the
‘outcome.’ Therefore, this study design can draw limited
inference with regard to relationships between exposure and
outcome.
In general, cross-sectional studies are prevalence studies
used to describe the burden of disease on a population in
terms of costs, life expectancy, morbidity, quality of life, or
other indicators and to describe the treatment provided to
specific patient groups. As a result, their findings can be used
for the planning of health care facilities. Thus, many cross-
sectional studies are descriptive instead of analytical studies.
As they play only a very limited role in studies on effects of
therapy, Figure 1 does not include this study design.
Occasionally, cross-sectional studies also collect informa-
tion on exposure in the past (e.g., smoking) or on exposure
that cannot change over time (e.g., genetic factors), and then
we do know that the exposure came first. In that situation,
their potential to answer research questions on etiology
increases, as they become similar to case–control studies. Also
in combination with information on later outcome (e.g., the
incidence of disease) in the same patients, cross-sectional
studies may contribute to the understanding of disease
etiology. Hallan et al.12 used data from population-based
surveys, a type of cross-sectional study, when they sought to
explain the difference in the incidence of end-stage renal
disease between Norway and the United States by comparing
Table 1 | Strengths and weaknesses of observational studies relating to etiology, diagnosis, prognosis, or adverse effects
aEach design may suffer from specific types of bias. These will be explained in one of the following papers.
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the prevalence of chronic kidney disease. Despite the much
lower incidence of end-stage renal disease in Norway, the
prevalence of chronic kidney disease was similar in both
countries.
Cross-sectional studies have some ability to generate
hypotheses that need further investigation in other study
designs. The choice of that design depends on the type of
research question. Despite their important weaknesses, cross-
sectional studies are frequently used, as they are fast and
inexpensive.
Case–control study
In case–control studies, patients are selected as cases on the
basis of the outcome variable. Looking back in time, the cases
are compared to a control group with regard to exposure.
This analytical study design is particularly efficient to
investigate rare outcomes. An example of such an outcome
studied in a case–control setting is congenital renal agenesis.13
The authors aimed to determine prenatal and perinatal
factors associated with the development of renal agenesis.
Cases were live birth infants with renal agenesis as reported in
a statewide birth registry; controls were a random sample of
all births in that registry that were not reported to have renal
agenesis. After adjustment for a number of factors, preexist-
ing maternal diabetes mellitus was associated with a higher
risk of renal agenesis. The data also suggested a positive
association with exposure to alcohol. Because renal agenesis
is a rare outcome and because it is not possible to study the
effect of exposure to alcohol in an RCT setting, a case–control
study design seems, indeed, the most efficient study design to
investigate this relationship.
Also genetic association studies frequently use case–-
control designs. For example, using 135 cases (diabetic
patients with diabetic nephropathy) and 107 controls
(diabetic patients without diabetic nephropathy) Janssen
et al.14 were able to show that diabetic patients with the
CNDP1–Mannheim variant were less susceptible to nephro-
pathy than others.
Case–control studies can study multiple exposures, but only
for their association with one outcome at the time. Controls
need to be selected carefully. The case–control design requires a
relatively small sample size, and is therefore an efficient design,
particularly in case of rare outcomes. These studies can be
performed relatively fast and are inexpensive. Results can be
used for hypothesis generation and testing.
Cohort study
Within a cohort study, a researcher composes a cohort of
subjects who are free of the outcome of interest. Depending
on the value of the exposure variable at the start of the study,
patients are classified in exposed and unexposed (control)
groups. Thereafter, patients will be followed over time to see
who will develop the outcome of interest and who will not.
de Mutsert et al.15 assessed body mass index at the start of
dialysis and recorded death during follow-up. They were able
to show that in hemodialysis patients, being underweight was
associated with an increased risk of death, but any effect of
obesity was not statistically significant. A well-known
example of a cohort study in nephrology is the international
Dialysis Outcomes and Practice Patterns Study (DOPPS), but
also studies from renal registries generally use a cohort
design.
As explained in the previous paper, cohort studies
investigating the effects of therapy can usually not provide
as much evidence for a causal relationship as an RCT. Despite
this superiority of RCTs in therapeutic studies, different
studies have shown that the estimate of the effect size derived
from well-conceived cohort studies often is remarkably
similar to that estimated in clinical trials.16,17
Cohort studies are analytical studies that have the
potential to provide answers to research questions on
etiology (e.g., smoking, alcohol, or genetic factors). The
strengths of cohort studies further lie in their potentially
larger sample sizes, as a result of their lower cost compared to
RCTs (though they are more expensive than case–control
studies) and in their broader patient populations resulting in
a higher generalizability of their results. Another strength is
that cohort studies enable investigators to study multiple
outcomes as well as multiple exposure variables. The DOPPS
may serve as a good example of that. Finally, cohort studies
on the effects of therapy may generate hypotheses and
provide an indication for the effect size, which is necessary
for sample size calculations. Both will assist in the design of
subsequent RCTs. In this respect, RCTs largely depend on
work from preceding observational studies. Observational
studies can, however, not replace RCTs.
CONCLUSION
Despite a number of objections, the RCT remains the
standard for studies on the effects of therapy. The hierarchy
of study designs, and the levels of evidence derived from it,
does hold for studies on the effects of therapy, provided such
studies are of sufficient quality. In contrast, in studies on
etiology, diagnosis, prognosis, or adverse effects, observa-
tional studies are much more important than RCTs, and in
those cases, any hierarchy of study designs is much less
useful, as specific problems may require specific solutions
with regard to study design. We conclude that both
observational studies and RCTs fulfill a complementary and
valuable role in nephrology. Clinicians using the evidence
from epidemiological studies should be aware of the strengths
and weaknesses of each study design.
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